4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Braf V600E mutation in melanoma: translational current scenario.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Melanoma was one of the translational cancer examples in clinic, including target therapy related to specific biomarkers impacting in the outcome of melanoma patients. Melanomagenesis involved a wide variety of mutations during his evolution; many of these mutated proteins have a kinase activity. One of the most cited proteins in melanoma is BRAF (about 50-60 % of melanomas harbors activating BRAF mutations), for these the most common is a substitution of valine to glutamic acid at codon 600 (p.V600E). Therefore, the precise identification of this underlying somatic mutation is essential; knowing the translational implications has opened a wide view of melanoma biology and therapy.

          Related collections

          Author and article information

          Journal
          Clin Transl Oncol
          Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
          Springer Nature
          1699-3055
          1699-048X
          Sep 2016
          : 18
          : 9
          Affiliations
          [1 ] Translational Medicine Laboratory, National Cancer Institute, San Fernando N.22, CP 14080, Mexico City, Mexico.
          [2 ] Translational Medicine Laboratory, National Cancer Institute, San Fernando N.22, CP 14080, Mexico City, Mexico. betzabe100@yahoo.com.
          [3 ] Laboratory of Translational Cancer Research and Cellular Therapy, Oncology Hospital, Medical Center Siglo XXI, Mexico City, Mexico.
          [4 ] National Cancer Institute, Mexico City, Mexico.
          [5 ] Genomics Sciences Program, Autonomous University of Mexico City, Mexico City, Mexico.
          Article
          10.1007/s12094-015-1469-6
          10.1007/s12094-015-1469-6
          26825657
          80f18074-0384-45c3-9b85-2c03a3291595
          History

          BRAF,Inhibitor resistance,Melanoma,V600E
          BRAF, Inhibitor resistance, Melanoma, V600E

          Comments

          Comment on this article